Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Johnson & Johnson (NYSE:JNJ) received FDA approval for its ...
Medical Device Network on MSN
FDA approves J&J’s TECNIS PureSee intraocular lens
The TECNIS PureSee IOL addresses both cataract-related vision loss and presbyopia, which affects near vision as eyes age.
Please provide your email address to receive an email when new articles are posted on . Combining extended depth of focus and trifocal IOLs improves distance vision without sacrificing near. A ...
Please provide your email address to receive an email when new articles are posted on . The extended depth of focus IOL has no warning on loss of contrast sensitivity. The lens will be available in ...
FDA has approved Johnson & Johnson's Tecnis PureSee IOL, an extended depth of focus (EDOF) intraocular lens (IOL) intended for use in cataract surgery. The new IOL will be available to U.S. patients ...
JACKSONVILLE, Fla., March 12, 2026--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) announced U.S. Food and Drug Administration (FDA) approval of TECNIS PureSee IOL, an extended depth of focus (EDOF) ...
(RTTNews) - Eye care firm Alcon Inc.(ALC) announced Tuesday that Vivity, an extended depth of focus or EDOF intraocular lens or IOL, is now available on the company's most advanced lens ...
FDA approval supports US commercialization of TECNIS PureSee, an EDOF IOL for implantation during cataract surgery, with availability anticipated later in 2026. PureSee is positioned to preserve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results